Indivior (NASDAQ:INDV) Given New $13.00 Price Target at Piper Sandler

Indivior (NASDAQ:INDV) had its target price reduced by research analysts at Piper Sandler from $16.00 to $13.00 in a note issued to investors on Thursday,Benzinga reports. The brokerage presently has an “overweight” rating on the stock. Piper Sandler’s price objective would indicate a potential upside of 29.87% from the company’s current price.

INDV has been the subject of several other reports. Rodman & Renshaw assumed coverage on Indivior in a report on Tuesday, January 28th. They issued a “buy” rating and a $16.00 price target for the company. RODMAN&RENSHAW upgraded Indivior to a “strong-buy” rating in a report on Tuesday, January 28th.

Indivior Price Performance

Shares of Indivior stock opened at $10.01 on Thursday. Indivior has a 1 year low of $7.33 and a 1 year high of $22.53. The business has a 50-day moving average of $11.02 and a two-hundred day moving average of $10.63. The company has a market capitalization of $1.38 billion, a P/E ratio of -28.60 and a beta of 0.73.

Indivior (NASDAQ:INDV) last announced its quarterly earnings results on Thursday, February 20th. The company reported $0.32 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.32. Indivior had a negative return on equity of 241.73% and a negative net margin of 3.96%. The company had revenue of $298.00 million during the quarter, compared to the consensus estimate of $262.35 million. On average, equities analysts anticipate that Indivior will post 1.22 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of INDV. Valence8 US LP acquired a new position in shares of Indivior during the third quarter worth about $564,000. Clark Estates Inc. NY acquired a new position in Indivior during the third quarter valued at approximately $2,477,000. Stonepine Capital Management LLC acquired a new position in Indivior during the third quarter valued at approximately $2,632,000. Zurcher Kantonalbank Zurich Cantonalbank boosted its position in Indivior by 4.8% during the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 41,327 shares of the company’s stock valued at $408,000 after purchasing an additional 1,888 shares during the last quarter. Finally, Rockefeller Capital Management L.P. boosted its position in Indivior by 66.7% during the third quarter. Rockefeller Capital Management L.P. now owns 50,000 shares of the company’s stock valued at $488,000 after purchasing an additional 20,000 shares during the last quarter. 60.33% of the stock is owned by institutional investors and hedge funds.

Indivior Company Profile

Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose.